

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

In Granada, 25 July 2014

RELEVANT FACT OF NEURON BIO

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB, Neuron Biopharma S.A. (hereinafter "NEURON BIO" or the "Company") hereby informs that:

The General Shareholders' Meeting of the company held in second call the 25 July 2014 with the attendance of present or represented shareholders holding 2 828 303 shares representing the 40.77 % of the social stock, has adopted unanimously all the proposals submitted by the Board of Directors for deliberation and vote according to the agenda:

1. Examination and approval, where appropriate, of the annual accounts corresponding to the financial year to 31 December 2013, as well as of the management of the Board of Directors during this financial year. Application of this result to 31 December 2013.
2. Removal and appointment of Directors and determination of their number.
3. Amendment of Bylaws and change of business name.
4. Renewal of the external account auditors.
5. Examination and approval, where appropriate, of the segregation of the neuroprotective drugs discovery business and the development and diagnostic tools license business for the creation of two new companies. These two companies, named NEEKEN DIAGNOSTICS, S.L. y NEPSIA THERAPEUTICS, S.L. will be fully owned by the Segregated Company. Approval of segregation balance sheets and approval of segregation project. Creation of the Qualifying Companies according to the segregation itself.
6. Application of the tax regimen applying to mergers, divisions, transfers of assets and exchanges of shares referred to in Chapter VIII of Title VII of the Revised Text of the Spanish Corporate Tax Law approved by Legislative Royal Decree 4/2004 of 5 March.
7. Delegation in the Board of Directors to increase the capital stock by issuing new

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

ordinary shares according to the article 297.1.(b) within the limits of the law with express power to exclude the preference subscription in accordance with what is established by Law. Delegation in the Board of Directors to stipulate the terms of the capital increase, to take required measures for implementation of the task, to adapt corresponding articles of the Articles of Association to the new amount of the capital stock and grant any public or private documents as deemed necessary to implement the capital increase. Request to competent national or international bodies in order to admit negotiation of new actions.

8. Delegation of powers for the execution, rectification and formalization of adopted agreements of the Board of Directors.
9. Requests and questions.
10. Approval of Minutes.

Finally, related to the second item of the agenda it is to emphasize that the General Shareholders' Meeting of the Company has decided to integrate in the Board of Directors seven members. At the same time the Board of Directors has appointed as members María Duñabeitia Mendialdua, Isabel María de Prada Guaita and José María Medina Jiménez.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors